Introduction A marked rise in the global prevalence of obesity and associated metabolic pathologies has been observed over the past 30 years ( Globally, more than 1 billion people are estimated to have NAFLD, including 83 million patients in the United States, making NAFLD the most common chronic liver disease in the US ( NASH is diagnosed histologically, based on the extent of steatosis, hepatocyte stress and damage (hepatocyte ballooning), immune infiltration (lobular inflammation), and degree of fibrosis ( While late-stage NASH greatly increases the risk of liver-related morbidity, NAFLD and NASH with less advanced fibrosis (i.e., F0F2) are associated with greatly increased risk of cardiovascular disease and related mortality ( Despite the unmet medical need, there is currently no approved therapy for NASH
Nanoparticle-based drug delivery systems in inhaled therapy: improving respiratory medicine
CasuCOikonomidouPRChenHNandiVGinzburgYPrasadPet alMinihepcidin peptides as disease modifiers in mice affected by -thalassemia and polycythemia Vera
Then, they were transfected with GSTM3 knockdown lentivirus (shGSTM3), scramble control lentivirus (shNC), GSTM3 overexpressing lentivirus (GSTM3-OE), and negative control (NC) lentivirus (GSTM3-NC) following the manufacturer's instructions
Archives of Biochemistry and Biophysics, 82 , 7077